Sculptor Capital’s Inovio Pharmaceuticals INO Stock Holding History

Sculptor Capital’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,333	Closed	-$2.69M	–	362
2020 Q2	$2.69M	Sell	8,333 -2,500	-23%	-$401K	0.02%	175
2020 Q1	$967K	Buy	+10,833	New	+$668K	0.01%	159

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sculptor Capital's INO Position: Q1 2022 in Review

Sculptor Capital sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 59,475 shares — an estimated $3.56M sold.

Sculptor Capital first reported a position in INO in Q1 2020 and held it in 8 quarters. The position peaked at $8.31M in Q2 2020. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

Sculptor Capital reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Sculptor Capital sold 59,475 Inovio Pharmaceuticals shares in Q1 2022, an estimated $3.56M.
Sculptor Capital first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Sculptor Capital's Inovio Pharmaceuticals position peaked at $8.31M in Q2 2020.
198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Sculptor Capital's 13F filing for Q1 2022, filed 13 May 2022.